Company: IXHL
Filing Date: 2025-04-16
Form Type: S-1/A
Source: 0001213900-25-032577
Chunk: 32

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-16
Form: S-1/A
Chunk 32
---
 shares of our Common Stock 
 after the date of this prospectus and prior to completion of this offering.                                                                |

| (5) | The shares reported under “Beneficially Ownership Prior to this                                                                                
 Offering” consist of 1,929,015 shares of Common Stock purchased in the Private Placement by L1 Capital Global Opportunities Master             
 Fund Ltd. (“L1 Capital”) and excludes 1,929,015 shares of Common Stock (subject to the adjustment and zero exercise price                      
 provisions of the Series A Warrants) underlying the Series A Warrants held by L1 Capital, the exercise of which are subject to receipt         
 of the Stockholder Approval and certain beneficial ownership limitations. 47,149,103 shares of Common Stock issuable upon the exercise         
 of the Series A Warrants held by L1 Capital are not registered for resale in this prospectus because they are subject to Stockholder Approval. 
 David Feldman and Joel Arber are the Directors of L1 Capital. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such      
 shares, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities. The principal business address of the L1 Capital          
 is 161A Shedden Road, 1 Artillery Court, PO Box 10085, Grand Cayman KY1-1001, Cayman Islands.                                                  |

| (6) | The shares reported under “Beneficially Ownership Prior to this                                                                                 
 Offering” consist of 1,929,015 shares of Common Stock purchased in the Private Placement by S.H.N Financial Investments Ltd (“S.H.N”)           
 and excludes 1,929,015 shares of Common Stock (subject to the adjustment and zero exercise price provisions of the Series A Warrants)           
 underlying the Series A Warrants held by S.H.N, the exercise of which are subject to receipt of the Stockholder Approval and certain beneficial 
 ownership limitations. 47,149,103 shares of Common Stock issuable upon the exercise of the Series A Warrants held by S.H.N. are not registered  
 for resale in this prospectus because they are subject to Stockholder Approval. Nir Shamir and Hadar Shamir have shared power to vote           
 and dispose of the securities held by S.H.N and may be deemed to be the beneficial owners of such shares of common stock. The business          
 address of S.H.N is Arik Einstein 3, Herzliya, Israel.                                                                                          |

| (7) |